| Code | CSB-RA006163MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to GIGA-564, targeting CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), a critical immune checkpoint receptor expressed primarily on T cells. CTLA4 functions as a negative regulator of T cell activation by competing with the co-stimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. By delivering inhibitory signals, CTLA4 maintains immune homeostasis and prevents excessive immune responses. Dysregulation of CTLA4 signaling is implicated in autoimmune diseases, while its inhibitory function is exploited by tumors to evade immune surveillance, making it a pivotal target in cancer immunotherapy research.
GIGA-564 is an anti-CTLA-4 monoclonal antibody, designed to block the binding of CTLA-4 to its ligand, thereby relieving the early inhibition of T cell activation and enhancing the anti-tumor immune response. GIGA-564 is currently in the preclinical or early clinical research stage. This biosimilar provides researchers with a reliable tool for studying T cell biology, immune checkpoint pathways, and mechanisms underlying immune-related disorders. It supports investigations into autoimmunity, transplant rejection, and tumor immunology, facilitating the development of therapeutic strategies targeting immune modulation.
There are currently no reviews for this product.